

Supplementary Figures and Tables

Figure S1: Mouse liver slides and human tissue microarrays following IHC staining with different concentrations of primary antibody targeting NCBP2 (A) and TFRC (B). All slides displayed at 40x magnification and scale bars indicate 50µm.

Figure S2: Boxplots showing the expression of each of *GMPS*, *RFC4*, *TFRC*, and *NCBP2* to be significantly upregulated in 3q22-3q29 patient samples as compared to non-amplified samples in the TCGA OSCC HPV-negative cohort.

Figure S3: 3q22-3q29 Amplification status is not significantly associated with OS (A), DSS (B) or PFI (C) in TCGA HPV-negative OSCC patients.

Figure S4: Scatter plot showing the expression of *TFRC* and *NCBP2* to be positively correlated to each other (*Spearman* ρ (R) = 0.68, $p < 2.2e-16$) in TCGA HPV-negative OSCC patients.

Table S1: Studies chosen for differential expression analysis

Dataset/Study	Number of Tumour samples	Number of normal samples
GSE3524 (Toruner <i>et. al.</i> 2004)	16	4
GSE9844 (Ye <i>et. al.</i> 2008)	26	38
GSE30784 (Chen <i>et. al.</i> 2008)	167	45
GSE13601 (Estilo <i>et. al.</i> 2009)	31	27
GSE31056 (Reis <i>et. al.</i> 2011)	23	25
TCGA HPV-negative OSCC	275	26

Table S2: Crosstabulation of NCBP2 and TFRC protein expression levels among 188 OSCC patients in the ORI cohort as determined by IHC staining of TMA slides. Spearman $\rho = 0.082$, $p = 0.283$.

		TFRC expression score				Total
		0	1	2	3	
NCBP2 expression score	0	2	0	0	1	3
	1	3	19	17	7	46
	2	4	27	32	11	74
	3	2	19	21	10	52
Total		11	65	70	29	175